Evidence map›Paper›PMID 27852052›Full record

SynthesisOncotarget2016

MicroRNAs for osteosarcoma in the mouse: a meta-analysis.

Junli Chang, Min Yao, Yimian Li, Dongfeng Zhao, Shaopu Hu, Xuejun Cui, Gang Liu, Qi Shi, Yongjun Wang, Yanping Yang

Open access · diamondAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Osteopontin in Bone Metabolism and Bone Diseases.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Junli ChangLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Min YaoLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yimian LiLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Dongfeng ZhaoLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shaopu HuLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xuejun CuiLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Gang LiuDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Qi ShiLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yongjun WangLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yanping YangLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Longhua Hospital Shanghai University of Traditional Chinese Medicine · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common primary malignant bone carcinoma with high morbidity that happens mainly in children and young adults. As the key components of gene-regulatory networks, microRNAs (miRNAs) control many critical pathophysiological processes, including initiation and progression of cancers. The objective of this study is to summarize and evaluate the potential of miRNAs as targets for prevention and treatment of OS in mouse models, and to explore the methodological quality of current studies. We searched PubMed, Web of Science, Embase, Wan Fang Database, VIP Database, China Knowledge Resource Integrated Database, and Chinese BioMedical since their beginning date to 10 May 2016. Two reviewers separately screened the controlled studies, which estimate the effects of miRNAs on osteosarcoma in mice. A pair-wise analysis was performed. Thirty six studies with enough randomization were selected and included in the meta-analysis. We found that blocking oncogenic or restoring decreased miRNAs in cancer cells could significantly suppress the progression of OS in vivo, as assessed by tumor volume and tumor weight. This meta-analysis suggests that miRNAs are potential therapeutic targets for OS and correction of the altered expression of miRNAs significantly suppresses the progression of OS in mouse models, however, the overall methodological quality of studies included here was low, and more animal studies with the rigourous design must be carried out before a miRNA-based treatment could be translated from animal studies to clinical trials.

Indexed as

AnimalsBiomarkers, TumorBone NeoplasmsChi-Square DistributionComputational BiologyDatabases, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksMaleMice, Inbred BALB CMice, Inbred C57BLMice, NudeMice, SCIDMicroRNAsBiomarkers, TumorMicroRNAsmeta-analysismiRNAmouseosteosarcomatherapeutic target

Identifiers

PMID27852052
PMCPMC5356766
OpenAlexW2554176882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.